Pathology: mGC or mGEJC - L1 - HER2 neg/PDL1 positive; mGC or mGEJC - L1 - HER2 negative; mGC or mGEJC - L1 - PDL1 positive; mGC or mGEJC - L2 - all population; mGC or mGEJC - L2 - PDL1 positive; mGC or mGEJC - M - HER2 negative; mGC or mGEJC - M - HER2 neg/PDL1 positive;
mGC or mGEJC - L1 - HER2 neg/PDL1 positive | mGC or mGEJC - L1 - HER2 negative | mGC or mGEJC - L1 - PDL1 positive | mGC or mGEJC - L2 - all population | mGC or mGEJC - L2 - PDL1 positive | mGC or mGEJC - M - HER2 negative | mGC or mGEJC - M - HER2 neg/PDL1 positive | |||||||||
CheckMate 649 (PDL1 CPS>5), 2021 | CheckMate 649 (PDL1 CPS>1), 2021 | CheckMate 649, 2021 | KEYNOTE-062 (P vs C ; CPS>10), 2020 | KEYNOTE-062 (P vs C ; CPS>1), 2020 | KEYNOTE-062 (PC vs C ; CPS>1), 2020 | KEYNOTE-062 (PC vs C ; CPS>10), 2020 | JAVELIN Gastric 300, 2018 | CA184-162, 2017 | ATTRACTION-2 (Kang), 2017 | KEYNOTE-061 (all population), 2018 | KEYNOTE-061 (PDL1 CPS>1), 2018 | JAVELIN Gastric 100, 2020 | JAVELIN Gastric 100 (PDL1>1%), 2020 | ||
pembrolizumab alone | 4 | T1 | T1 | T1 | T1 | ||||||||||
nivolumab plus SoC | 3 | T1 | T1 | T1 | |||||||||||
avelumab alone | 3 | T1 | T1 | T1 | |||||||||||
pembrolizumab plus SoC | 2 | T1 | T1 | ||||||||||||
Ipilimumab (10 mg/kg) | 1 | T1 | |||||||||||||
nivolumab alone | 1 | T1 | |||||||||||||
placebo plus SoC | 0 | T0 | T0 | T0 | |||||||||||
Standard of Care (SoC) | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | ||||||
paclitaxel | 0 | T0 | T0 | ||||||||||||
placebo | 0 | T0 |